ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on March 29, 2018. The company is incorporated in Delaware and is designated as an emerging growth company. The report addresses corporate governance matters related to the upcoming 2018 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder meeting logistics and does not contain financial performance data.
Material Changes
No material changes to financial operations or business strategy are reported in this document. The primary update is the scheduling of the Annual Meeting and the establishment of deadlines for shareholder nominations.
Guidance, Outlook, and Corporate Actions
- Annual Meeting: Scheduled for Tuesday, May 8, 2018. Specific time and location will be detailed in the proxy statement.
- Record Date: Set at the close of business on March 30, 2018, to determine stockholders entitled to vote.
- Nomination Deadline: Stockholders must submit notices for director nominations or other business proposals by the close of business on April 9, 2018.
- Submission Requirements: Notices must be delivered to the Corporate Secretary at the company's principal executive offices in Ann Arbor, Michigan, and must comply with Delaware law and SEC regulations.
Key Facts for Investor Verification
- Verify the specific time and location of the Annual Meeting once the proxy statement is released.
- Confirm the April 9, 2018 deadline for submitting shareholder proposals or director nominations.
- Ensure any nomination notices are addressed to the Corporate Secretary at 3600 Green Court, Suite 350, Ann Arbor, MI 48105.
- Note that the company is classified as an emerging growth company.